Proactive's Tylah Tully breaks down ‘Just the Facts’ of the latest news from Arovella Therapeutics Ltd (ASX:ALA).
The company has raised $20 million, including a $15 million cornerstone investment, to fully fund its Phase 1 clinical trial for ALA-101, a CAR-iNKT cell therapy targeting CD19-positive blood cancers.
The funding will also support the company’s invariant Natural Killer T (iNKT) cell therapy pipeline and solid tumour programs.
The capital raise was executed through a placement of 117.6 million shares at $0.17 each, attracting strong support from institutional investors like Pengana Capital Group and a $15 million commitment from an unnamed Australian private investor.
Post-raise, Arovella holds $30.6 million in cash and cash equivalents, enabling it to secure IND approval from the US FDA for a Phase 1 trial targeting CD19-positive non-Hodgkin's lymphoma and leukaemia, commence and gather clinical data from the trial, and advance proof-of-concept data for its solid tumour programs focused on gastric and pancreatic cancers.
The company emphasised that the raise demonstrates confidence in its CAR-iNKT platform and positions it as a leader in cell therapy innovation.